Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Article

Part 1 - Preparing for a Risk-Based Future: What ICH Revisions Mean for Clinical Trial Design and Conduct

Sep 14, 2021

Blog

Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity

Mar 3, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Blog

Biosimilar Development: Are therapeutic clinical trials needed?

Nov 16, 2021

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

3 ways to incorporate DE&I in your communications strategy

Sep 29, 2021